Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
4.81B | 5.51B | 6.22B | 5.44B | 4.69B | Gross Profit |
626.00M | 733.00M | 997.00M | 574.00M | 720.00M | EBIT |
110.00M | 28.00M | 405.00M | 229.00M | 283.00M | EBITDA |
440.00M | 641.00M | 1.11B | 619.00M | 576.00M | Net Income Common Stockholders |
-133.00M | -223.00M | 318.00M | 33.00M | -10.00M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
146.00M | 164.00M | 531.00M | 197.00M | 458.00M | Total Assets |
5.88B | 6.39B | 7.31B | 7.02B | 6.84B | Total Debt |
3.70B | 3.87B | 4.41B | 4.54B | 4.25B | Net Debt |
3.56B | 3.70B | 3.88B | 4.34B | 3.80B | Total Liabilities |
4.77B | 5.05B | 5.75B | 5.73B | 5.77B | Stockholders Equity |
1.10B | 1.34B | 1.55B | 1.28B | 1.07B |
Cash Flow | Free Cash Flow | |||
395.00M | 249.00M | 156.00M | -21.00M | -157.00M | Operating Cash Flow |
395.00M | 534.00M | 414.00M | 261.00M | 253.00M | Investing Cash Flow |
-156.00M | -272.00M | 102.00M | -658.00M | -354.00M | Financing Cash Flow |
-275.00M | -633.00M | -193.00M | 147.00M | -711.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
71 Outperform | $17.56B | 21.89 | 19.03% | 2.56% | 7.45% | 5.26% | |
67 Neutral | $4.23B | 15.71 | 45.91% | 2.76% | -1.75% | -21.15% | |
66 Neutral | $28.00B | 33.84 | 6.74% | 3.48% | -1.57% | 84.85% | |
65 Neutral | $7.84B | 12.11 | 22.72% | 1.53% | -6.59% | -7.81% | |
64 Neutral | $4.61B | 28.28 | 6.42% | 4.45% | -6.93% | -65.66% | |
59 Neutral | $12.24B | 11.04 | -1.00% | 3.78% | 1.30% | -19.54% | |
54 Neutral | $3.24B | ― | -11.10% | 2.23% | -6.57% | 38.96% |
On March 28, 2025, Pactiv Evergreen announced that it had received all required regulatory approvals for its acquisition by Novolex, which is expected to close on April 1, 2025. The transaction will result in Pactiv Evergreen becoming a privately held company, with its common stock no longer listed on Nasdaq, marking a significant shift in its market presence.
Pactiv Evergreen Inc. announced the expiration of the Hart-Scott-Rodino Act waiting period on January 21, 2025, in relation to its planned acquisition by Novolex Holdings, LLC. The merger, valued at $18.00 per share, is expected to close in the second quarter of 2025, subject to foreign antitrust approvals and other conditions, resulting in Pactiv Evergreen becoming a privately held company and delisting from Nasdaq.